PHARMACEUTICAL IP

  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
    • Oppositions and appeals
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
    • Oppositions and appeals
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Evolve Insights

Welcome to Evolve Insights!

Evolve Insights is your go-to source for expert analysis and strategic perspectives on pharmaceutical IP.

  • Read our Articles for the latest pharma IP news and analysis. Many of our articles were originally published on IPKat.
  • Register for our upcoming live Webinars and watch our previous webinars on-demand.
  • Subscribe to our newsletter to stay up to date.

Do you have questions about how the latest developments in IP might impact you? Our team of experts would love to hear from you.

Latest articles

All articles

Optogenetics wins the 2026 Nobel Prize in Physiology or Medicine

  • 13th October 2026
Congratulations to Professor Karl Deisseroth (The Howard Hughes Medical Institute and Stanford University), Professor Peter Hegemann (Humboldt University of Berlin) and Professor Georg Nagel (University of Würzburg), who were jointly awarded the 2026 Nobel Prize in Physiology or Medicine for their discoveries concerning light-gated ion channels and their pioneering contributions to the field of optogenetics.…

G1/25: What are the consequences?

  • 9th October 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly (Evolve Insights).

Webinars

All webinars
  • On-demand

Unlocking the potential of cell & gene therapies with effective IP strategy

Recorded on: July 11, 2025
Discover how to transform ground-breaking cell & gene therapy science into commercial success with robust IP strategies.
Previous Next

Stay connected

Get the latest insights, news, and expert analysis on pharmaceutical IP delivered straight to your inbox.
Subscribe for updates

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us